Suppressive effect of saprogrelate hydrochloride on Raynaud's phenomenon and respiratory failure in patients with systemic sclerosis

Respirology

Volumn 5, Issue 1, 2000, Pages 27-32

  Kato, Shiro ^a,c   Kishiro, Izumi ^a   Ohnuma, Noboru ^a   Takasaki, Keiji ^a   Okamoto, Shingo ^a   Nakamoto, Takaaki ^a   Kaneko, Noboru ^a   Kumamoto, Hidero ^b  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Tokyo Tanabeseiyaku Co Ltd   (Japan)

^c NONE   (Japan)

Author keywords

Raynaud's phenomenon; Saprogrelate hydrochloride; Systemic sclerosis

Indexed keywords

BETA THROMBOGLOBULIN; C REACTIVE PROTEIN; FIBRINOPEPTIDE A; SAPROGRELATE HYDROCHLORIDE; SEROTONIN 2 ANTAGONIST; THROMBOCYTE FACTOR 4; THROMBOMODULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL GAS; ARTERIAL OXYGEN TENSION; ARTICLE; CLINICAL ARTICLE; COLD; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFECT; FEMALE; HUMAN; LEUKOCYTE COUNT; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MALE; PAIN; PARESTHESIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAYNAUD PHENOMENON; RESPIRATORY FAILURE; SYSTEMIC SCLEROSIS;

ADULT; AGED; BETA-THROMBOGLOBULIN; BLOOD PRESSURE; C-REACTIVE PROTEIN; FEMALE; FIBRINOPEPTIDE A; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PLATELET FACTOR 4; PULMONARY ARTERY; PULMONARY FIBROSIS; PULMONARY VENTILATION; RAYNAUD DISEASE; RESPIRATORY INSUFFICIENCY; SCLERODERMA, SYSTEMIC; SEROTONIN ANTAGONISTS; THROMBOMODULIN;

EID: 0034064309     PISSN: 13237799     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1843.2000.00222.x     Document Type: Article

References (15)

1. Masi AT, Rodman GP, Medsger TA et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1986; 23: 581-90.
2. Bennet R, Bluestone R, Halt PJC, Bywaters EGL. Survival in scleroderma. Ann. Rheum. Dis. 1971; 30: 581-8.
3. Seibold JR. Serotonin and Raynaud's phenomenon. J. Cardiovasc. Pharmacol. 1985; 7: 95-8.
4. Coffman JD, Clement DL, Creager MA et al. International study of Ketanserin in Raynaud's phenomenon. Am J. Med. 1989; 87: 264-8.
5. 2-serotonergic receptor antagonist. Thoromb. Haemostas. 1991; 65: 415-20.
6. LeRoy EC, Krieg T, Black C et al. Scleroderma (systemic sclerosis: Classification, Subsets and pathogenesis.) J. Rheumatol. 1998; 15: 202-5.
7. Ali D, Gregory M, Julius MG et al. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am. J. Cardiol. 1987; 59: 662-8.
8. American Thoracic Society. Standardization of spirometry: 1987 update ATS statement. Am. Rev. Resp. Dis. 1987; 136: 1285-98.
9. Coffman JD, Cohen A. Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon. Clin. Sci. 1994; 86: 269-73.
10. Aalbers R, Groen H, Postma DS et al. Pulmonary function in patients presenting with Raynaud's phenomenon without an underlying connective tissue disease. A prospective, longitudinal study. J. Rheumatol. 1989; 16: 36-41.
11. Golden MD, Wise RA, Schneider P, Hochberg M, Stevens MB, Wigley F. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Madicine 1984; 63: 221-31.
12. Fanti S, Fabritiis A, Aloisi D et al. Early pulmonary involvement in systemic sclerosis assessed by technetium-99m-DTPA clearance rate. J. Nucl. Med. 1995; 35: 1933-6.
13. 3H] ketanserin for serotonin-2 receptor in the rabbit platelet. Pharmacobio-Dyn. 1991; 14: 461-6.
14. Higashino H, Suzuki A. Endothelin participates in a process of fibrinogen-involved platelet aggregation. Acta. Med. Kinki Univ. 1997; 22: 127-30.
15. Soslau G, Sivergerg M, Bredsky I, McCarty PP. ATP modification of serotonin-induced contraction of the rat pulmonary artery. P. S. E. B. M. 1997; 214: 233-41.